期刊文献+
共找到1篇文章
< 1 >
每页显示 20 50 100
Treatment of secondary central nervous system involvement in systemic aggressive B cell lymphoma using R-MIADD chemotherapy:a single-center study
1
作者 Yuchen Wu Xuefei Sun +12 位作者 Xueyan Bai Jun Qian Hong Zhu Qu Cui Ruixian Xing Yuedan Chen Qing Liu Wenyuan Lai Junhong Li Yaming Wang Shengjun Sun Nan Ji Yuanbo Liu 《Chinese Neurosurgical Journal》 CSCD 2021年第2期143-150,共8页
Background:Secondary central nervous system lymphoma(SCNSL)is defined as lymphoma involvement within the central nervous system(CNS)that originated elsewhere,or a CNS relapse of systemic lymphoma.Prognosis of SCNSL is... Background:Secondary central nervous system lymphoma(SCNSL)is defined as lymphoma involvement within the central nervous system(CNS)that originated elsewhere,or a CNS relapse of systemic lymphoma.Prognosis of SCNSL is poor and the most appropriate treatment is still undetermined.Methods:We conducted a retrospective study to assess the feasibility of an R-MIADD(rituximab,high-dose methotrexate,ifosfamide,cytarabine,liposomal formulation of doxorubicin,and dexamethasone)regimen for SCNSL patients.Results:Nineteen patients with newly diagnosed CNS lesions were selected,with a median age of 58(range 20 to 72)years.Out of 19 patients,11(57.9%)achieved complete remission(CR)and 2(10.5%)achieved partial remission(PR);the overall response rate was 68.4%.The median progression-free survival after CNS involvement was 28.0 months(95%confidence interval 11.0–44.9),and the median overall survival after CNS involvement was 34.5 months.Treatment-related death occurred in one patient(5.3%).Conclusions:These single-centered data underscore the feasibility of an R-MIADD regimen as the induction therapy of SCNSL,further investigation is warranted. 展开更多
关键词 Central nervous system B cell lymphoma SCNSL r-miadd CHEMOTHERAPY
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部